Search

everythinglearnresearchcommunity

for

Search:↓

A 43-year-old male with advanced hair loss is experimenting with alternative treatments, including red light therapy, microneedling, scalp massages, an oil mix, and ketoconazole shampoo, after previously experiencing side effects from finasteride and minoxidil. He noticed some minor changes with red light therapy but remains skeptical about significant improvement.

The conversation discusses the ineffectiveness of dutasteride in halting hair loss for the user and explores the potential of PP405, which works through a different mechanism. Suggestions include considering a biopsy to determine the cause of hair loss and exploring other treatments like RU58841.

PP405, a topical treatment, shows promise for hair growth by activating inactive follicles, with 66% of participants experiencing positive results. The treatment is well-tolerated and may proceed directly to Phase 3 trials, offering a potential alternative to minoxidil and finasteride.

DHT, not testosterone, causes hair loss. Treatments like finasteride, dutasteride, and RU58841 target DHT to manage hair loss.

GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.

Red light therapy for hair loss is controversial, with mixed results reported. Its effectiveness may depend on device quality and proper wavelength, and it is often used with minoxidil and finasteride.

The conversation suggests that abstaining from ejaculation for a few months may help stop or reverse hair loss by potentially increasing testosterone and reducing DHT levels. It also mentions the use of minoxidil and finasteride as effective treatments for maintaining hair after a hair transplant.

A 28-year-old male is experiencing temple regrowth but crown thinning while using 5mg minoxidil and 0.5mg dutasteride. The shedding phase is seen as a positive sign of treatment effectiveness, with expectations of noticeable improvements around 6 to 12 months.

RU58841 5% is theoretically equivalent to 2mg of dutasteride for hair loss treatment, with RU58841 offering higher potential but more variability due to absorption issues. Users discuss the effectiveness of RU58841 and dutasteride, with some preferring dutasteride for consistent results and others finding success with RU58841.

The user has experienced significant hair regrowth over 2 years and 3 months using 0.5mg dutasteride and 5mg oral minoxidil, with noticeable improvement in the temples and crown. The user is considering a hair transplant but is encouraged by others to continue with the current treatment due to the impressive results.

Saw palmetto, a 5-alpha reductase inhibitor, caused unexpected side effects like breast changes and altered semen consistency, which resolved after stopping its use. Concerns about similar side effects with finasteride or dutasteride were expressed, and another user reported low libido and depression from saw palmetto.

The user shared six months of progress using oral finasteride (1.2mg) and minoxidil (3mg) with positive results. They do not use topical minoxidil and have not experienced side effects like erectile dysfunction.

The conversation discusses using a TCA 35% chemical peel on the scalp to potentially improve hair growth by addressing fibrosis and enhancing the effectiveness of topical treatments. The user also mentions trying microneedling and other methods like topical metformin and dutasteride for hair regrowth.

A 49-year-old is using minoxidil, finasteride, and supplement chews for hair growth, experiencing thick growth except on the top, and seeking advice on improving density. Suggestions include continuing treatment, considering additional options like oral minoxidil, ketoconazole shampoo, dermapen, and possibly a hair transplant, though cost is a concern.

Hair loss can cause psychological distress, but maintaining optimism and self-improvement is crucial. Treatments like minoxidil, finasteride, and potential new options like clascoterone offer hope, though side effects can occur.

Finasteride has stabilized hair loss but hasn't led to significant regrowth. Adding minoxidil is suggested for better regrowth results.

A 24-year-old experienced improved hair growth using 5% minoxidil, 1 mg finasteride, and dermastamping, but faced side effects like low libido and mild erectile dysfunction. They plan to reduce finasteride dosage after full results and may consider a hair transplant if thinning recurs.

Oral minoxidil is considered more convenient and effective for some users, with positive results reported, but concerns about side effects and availability persist. Finasteride remains a standard treatment, while some users explore combinations with other treatments like dutasteride and laser devices.

Tretinoin can increase hair follicles and is used alongside minoxidil and finasteride for hair growth, though it may cause skin peeling. Users report varying results, with some experiencing regrowth and others questioning its efficacy for hair.

The user is considering another hair transplant or scalp micropigmentation (SMP) for a congenital bald spot, but previous transplants were less effective due to scar tissue. Suggestions include using hair fibers, changing hairstyles, or doing nothing, as the spot is not very noticeable.

Liver problems may reduce the effectiveness of oral minoxidil due to impaired SULT1A1 enzyme activity, which is crucial for converting minoxidil to its active form. This reduction in enzyme function can significantly decrease the drug's effectiveness in promoting hair growth.

Minoxidil and dermarolling can yield positive hair growth results, but long-term effectiveness varies, and some users experience hair loss again without additional treatments like finasteride. Microneedling enhances minoxidil's effectiveness by increasing enzyme activity, but individual experiences differ.

Hair follicle stem cells remain in bald individuals, but progenitor cells do not, raising questions about hair regrowth claims by Pelage. PP405 is discussed as a potential treatment, with skepticism about its effectiveness compared to existing treatments like Minoxidil and Finasteride.

Finasteride is humorously claimed to enable communication with sea mammals, with users sharing exaggerated side effects and alternative hair loss treatments like olive oil and onion. The conversation is satirical, with users joking about unusual experiences and results.

Several new hair loss treatments are in development, with Cosmo Breezula and Kintor KX826 being the furthest along, expected to be commercialized by 2027. Veradermics is the only treatment in pill form, while others like KX/GT/Breezula will be topical.

Stevia microneedles increased minoxidil absorption and hair growth in mice. The conversation humorously questions the applicability of these results to humans.

Pelage plans to conduct two Phase 3 trials for PP405, a new hair loss treatment, which may take about a year to complete. Users discuss various hair loss treatments, including pyrilutamide, minoxidil, finasteride, and clascoterone, with some expressing impatience over the lengthy trial process compared to faster drug approvals like the COVID vaccine.

A 19-year-old is considering switching from topical to oral minoxidil to combat hair loss, despite concerns about increased body hair. They are currently using minoxidil, ketoconazole shampoo, and dutasteride, and are willing to accept the trade-off of more body hair for better scalp hair growth.

Clascoterone 5% solution is discussed as a potential new treatment for hair loss, offering an alternative for those who can't use finasteride or need additional options beyond minoxidil. Concerns about cost, effectiveness, and safety compared to existing treatments like RU58841 and finasteride are highlighted.

Some people have side effects from finasteride and dutasteride due to hormonal predisposition, especially if DHT dominant. Alternatives like RU58841, Pyrilutamide, and Breezula are suggested to target scalp androgen receptors without altering overall hormones.